Xarelto for Long-term and Initial Anticoagulation in Venous Thromboembolism
Phase of Trial: Phase IV
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Deep vein thrombosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms XALIA
- Sponsors Bayer
- 12 Dec 2017 Results of pooled analysis of the XALIA and XALIA-LEA studies assessing tolerability and efficacy of rivaroxaban in patients with acute venous thromboembolism, were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 06 Dec 2016 Results of a subgroup analysis in patients with cancer (n=587), presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 06 Dec 2016 Subgroup analysis results published in a Janssen Pharmaceuticals media release.